共 13 条
[1]
ANG SL, 1995, PHARMACOGENETICS, V5, P37
[2]
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[5]
Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California
[J].
PHARMACOGENETICS,
1996, 6 (06)
:527-533
[7]
Genetic analysis of CYP2C9 polymorphism in a Japanese population
[J].
PHARMACOGENETICS,
1997, 7 (05)
:405-409
[8]
IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9
[J].
PHARMACOGENETICS,
1994, 4 (01)
:39-42
[9]
Genetic analysis of the human cytochrome P450 CYP2C9 locus
[J].
PHARMACOGENETICS,
1996, 6 (05)
:429-439
[10]
The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism
[J].
PHARMACOGENETICS,
1996, 6 (04)
:341-349